Emcure Pharmaceuticals (NSE:EMCURE) ROCE %: 27.20% (As of Mar. 2026)


NSE:EMCURE Emcure Pharmaceuticals Ltd NSE:EMCURE
41 GF Score
Price ₹1,880.20
! 5 Warning Signs
View Full Analysis

What is Emcure Pharmaceuticals ROCE %?

Emcure Pharmaceuticals NSE:EMCURE +2.18% 41 ROCE % is 27.20% as of Mar. 2026. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Emcure Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 27.20%.

Emcure Pharmaceuticals  (NSE:EMCURE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Emcure Pharmaceuticals ROCE % Related Terms

Emcure Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Emcure Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emcure Pharmaceuticals ROCE % Chart

Emcure Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial 34.01 26.96 22.50 22.58 25.40

Emcure Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.54 22.82 26.21 24.66 27.20
NSE:EMCURE
41GF Score
Emcure Pharmaceuticals Ltd NSE:EMCURE
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emcure Pharmaceuticals ROCE % Calculation

Emcure Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=14308.16/( ( (82327.23 - 26682.71) + (96124.81 - 39122.41) )/ 2 )
=14308.16/( (55644.52+57002.4)/ 2 )
=14308.16/56323.46
=25.40 %

Emcure Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=15503.08/( ( (0 - 0) + (96124.81 - 39122.41) )/ 1 )
=15503.08/( ( 0 + 57002.4 )/ 1 )
=15503.08/57002.4
=27.20 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 27.20% mean?
Emcure Pharmaceuticals (NSE:EMCURE) has a ROCE % of 27.20% as of Mar. 2026.
Is Emcure Pharmaceuticals' ROCE % too high?
Emcure Pharmaceuticals' current ROCE % is 27.20%. The Drug Manufacturers industry median ROCE % is 7.01. Emcure Pharmaceuticals' value of 27.20% is 288% above this industry median. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' ROCE % compare to ZTS and UTHR?
Emcure Pharmaceuticals' ROCE % of 27.20% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. Emcure Pharmaceuticals' value of 27.20% is 288% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emcure Pharmaceuticals's current ROCE % of 27.20% is 288% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emcure Pharmaceuticals's current ROCE % is 27.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current ROCE % of 27.20%. The current ROCE % is 27.20% and 288% above the Drug Manufacturers industry median of 7.01. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current ROCE % is 27.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emcure Pharmaceuticals Business Description

Other Exchanges 544210:India
Address Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune, MH, IND, 411 057
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score

Get the complete analysis for NSE:EMCURE

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,880.20
Price